{"id":"W4391301902","doi":"10.1200/jco.2024.42.4_suppl.116","title":"Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Hormonal therapy; Internal medicine; Subgroup analysis; Cancer; Pathology; Alternative medicine; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002318081,0.0007712165,0.001697003,0.0004644293,0.000178098,0.0006151754,0.000408794,0.0005792202,0.001978149],"category_scores_gemma":[0.001547153,0.0002524299,0.003992997,0.0004804032,0.0003039948,0.0004676571,0.0004206905,0.0009402099,0.000199017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004281276,"about_ca_system_score_gemma":0.0004603952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006173748,"about_ca_topic_score_gemma":0.001723192,"domain_scores_codex":[0.9990435,0.0005204641,0.00009884734,0.0001390535,0.0001001365,0.00009788739],"domain_scores_gemma":[0.9992135,0.000256168,0.0003079452,0.00004614474,0.00003482663,0.0001415038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9045234,0.001882824,0.04122538,0.0009290955,0.01710485,0.0000822104,0.00009825588,0.002031653,0.003094291,0.00008067892,0.0005896871,0.02835766],"study_design_scores_gemma":[0.2575512,0.3373871,0.3512764,0.0002361496,0.0396806,0.0004015615,0.000346902,0.006254049,0.003805572,0.0005298947,0.002410193,0.0001203889],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955717,0.002732765,0.0001417975,0.00008202995,0.00003252509,0.0002123219,0.0007975175,0.00001015936,0.0004191021],"genre_scores_gemma":[0.9980662,0.0005262953,0.0001521497,0.0000720214,0.00004003651,0.0002271756,0.0006625293,0.000002583895,0.0002509429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002318081,"threshold_uncertainty_score":0.01225936,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0822781094013292,"score_gpt":0.4305449757794088,"score_spread":0.3482668663780796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}